ClinicalTrials.gg
Active, not recruitingNCT04228991RHEALUpdated Oct 13, 2026

Hypofractionated LocoRegional Radiotherapy in Breast Cancer

A Phase 3 interventional study of Locoregional radiation treatment - Conventional fractionation and Locoregional radiation treatment - Hypofractionation in Breast Neoplasms, Radiotherapy and Lymphedema, sponsored by Ontario Clinical Oncology Group (OCOG). Active, not recruiting at 20 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) — 2 open to participants now, 4 under way, 2 of them phase 3. Breast Neoplasms · Ontario Clinical Oncology Group (OCOG).

Planned enrollment
7th of 20
588 · median 318
Started
2021
the only one that year
Phase 3
5 of 24
1 open now
Registered
22nd of 24
by date

Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2021, is one of 5 in phase 3, and was the 22nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), or all of them as a file.
02

Study summary

The primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to conventional fractionation to the breast or chest wall and regional nodes delivered over 3 weeks (40Gy in 15 daily fractions) in patients with node-positive breast cancer.

Read the detailed description

A multi-centre, randomized, non-inferior, phase III study comparing two radiation treatment modalities, conventional fractionation with hypofractionation for locoregional RT. Eligible, consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of the breast without evidence of metastatic disease; treated with definitive surgery [BCS or mastectomy with nodal staging using sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)] will be randomized in a 1:1 fashion to either conventional locoregional RT (control group) or hypofractionated locoregional RT (experimental group). Stratification factors include: body mass index, the performance of ALND, type of surgery (BCS or mastectomy) and clinical centre.

Study participants will be assessed for lymphedema, the primary outcome, by measuring arm volume. Arm mobility will be assessed by measuring arm movement. Study participants will be assessed for acute and late radiation toxicities, during and post RT. Study participants will be followed and assessed annually for breast cancer recurrence (BCR), new second cancers, quality of life (QOL) and overall survival. Cost effectiveness and cost utility will also be determined. The planned sample size is 588 study participants. The study will be conducted at clinical centres throughout Canada.

03

Conditions studied

  • Breast Neoplasms
  • Radiotherapy
  • Lymphedema

Keywords

  • Hypofractionated
  • Locoregional
  • Breast Cancer
  • Lymphedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed invasive carcinoma of the breast.
  2. Treated with definitive surgery (BCS or mastectomy with nodal staging using SLNB or ALND) with clear margins of excision.* Note: *Patients with limited positive posterior margin where disease is resected to chest wall or limited positive anterior margin where disease is resected to dermis are eligible.
  3. Candidate for locoregional radiotherapy: breast cancer stage after definitive surgery:

    • chemotherapy was not administered: pathologic stage T3N0,T1-3 N1-2**

      ** patients with nodal micromets (N1mi) are eligible

    • Neoadjuvant chemotherapy was administered: clinical stage T3N0, T1-3, N1-2 and pathologic stage T0-3, N0-2†

      • Patients who are clinically N1-2 prior to chemotherapy should be confirmed histologically unless it is clear that they are node positive. Patients who are deemed node negative prior to chemotherapy but are node positive following chemotherapy are eligible. Patients who are node positive prior to chemotherapy and who have complete response in the lymph nodes are also eligible.
  4. No evidence of disease.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years.
  2. Clinical stages T4 and/or N3.
  3. Clinical lymphedema in the ipsilateral arm or breast/chest wall.
  4. Any prior history, not including index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with previous ipsilateral DCIS or LCIS not treated with radiation are eligible.)
  5. Synchronous or previous contralateral breast cancer.(Patients with previous contralateral DCIS or LCIS not treated with radiation are eligible.)
  6. History of non-breast within the last 5 years other than non-melanoma skin cancer or treated in-situ carcinoma.
  7. endocrine therapy. (Extended neoadjuvant endocrine therapy is not permitted. Endocrine therapy exposure for 12 weeks or less prior to surgery is acceptable.)
  8. Breast reconstruction.
  9. Presence of known medical conditions that would preclude follow-up for 5 years.
  10. Previous radiotherapy to the ipsilateral breast or chest wall or serious non-malignant disease e.g. scleroderma, severe lung or heart disease that would preclude radiotherapy.
  11. Known pregnancy or currently lactating.
  12. Geographic inaccessibility for follow-up.
  13. Inability to provide .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
588 participants (estimated)

Study arms

  • Active comparator
    Control

    Conventional fractionation for locoregional radiotherapy

    Radiation: Locoregional radiation treatment - Conventional fractionation

  • Experimental
    Experimental

    Hypofractionation for locoregional radiotherapy

    Radiation: Locoregional radiation treatment - Hypofractionation

Interventions

  • RadiationLocoregional radiation treatment - Conventional fractionation

    40 Gray in 15 daily fractions over 3 weeks

  • RadiationLocoregional radiation treatment - Hypofractionation

    26 Gray in 5 daily fractions over 1 week

06

What researchers measure

Primary outcomes

  1. Lymphedema

    Lymphedema defined as relative volume change (RVC) ≥10%

    Time frame: 3 years post randomization

Secondary outcomes

  1. Breast cancer recurrence

    Both locoregional and distant recurrence and second cancers

    Time frame: Annually for 5 years post randomization

  2. Mortality

    Survival

    Time frame: Annually for 5 years post randomization

  3. Radiation toxicity

    Acute and late radiation toxicity

    Time frame: During last week of radiotherapy, at 3 months post radiotherapy and annually for 5 years post randomization

  4. Arm mobility

    Assessed by measuring the straight lateral abduction of both the ipsilateral and contralateral arm

    Time frame: 1 and 3 years post randomization

  5. Patient Quality of Life with respect to daily health and activities

    Impact on quality of life will be assessed with the European Organization for Research in Treatment of Cancer and the Breast Cancer Specific Module 23. The scale is 1 to 4 where a higher score means a worse outcome.

    Time frame: During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization

  6. Perception of lymphedema

    Impact of lymphedema on quality of life will be assessed with the National Surgical Adjuvant Breast and Bowel Project questionnaire. The scale is 1 to 5 where a higher score means a worse outcome.

    Time frame: During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization

  7. Perception of breast cosmesis

    Patient-reported breast cosmesis using a Breast Cosmesis Questionnaire to study the late effects of radiation.

    Time frame: 1 and 3 years post randomization

  8. Health Care Resource Utilization

    Health Care Resource Utilization will be estimated using dates and duration of radiotherapy treatment and emergency department visits and hospitalizations.

    Time frame: During radiotherapy, at 3 months post radiotherapy and annually for 5 years post randomization

  9. Patient Costs

    Patient costs will be assessed using a Time Off Work Questionnaire to study the financial impact of breast cancer and its treatment

    Time frame: During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization

07

Study locations

20 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Jul 2028, 89 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 89 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2020
First posted
Jan 14, 2020
StartActual
Feb 10, 2021
Primary completionEst.
Jul 2028
CompletionEst.
Dec 31, 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04228991
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Collaborators
Canadian Institutes of Health Research (CIHR), McMaster University
Responsible party
Sponsor
First posted
Jan 14, 2020
Start date
Feb 10, 2021
Primary completion
Jul 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

Timothy Whelan, MD
principal investigator · Juravinski Cancer Centre, McMaster University, Hamilton

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion